Acurx Pharmaceuticals, Inc. (NasdaqCM: ACXP)
Health Care · Biotechnology · US
$1.14
-0.44% today · -82.5% 1Y
Acurx Pharmaceuticals, Inc. (NasdaqCM: ACXP) operates in the Biotechnology industry within the Health Care sector. The company is valued at $5.98M and employs 4 people.
Over the last twelve months the share price has lost 82.5%, trading between 1.07 and 7.54.
Tweenvest scores Acurx Pharmaceuticals, Inc. across four factors: quality 35/100, value 24/100. Its strongest factor is quality.
ACXP price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $5.98M
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -2.78
- Dividend yield
- —
- Beta (5Y)
- -2.05
- 52-week high
- $7.54
- 52-week low
- $1.07
- Avg volume (3M)
- —
- Shares outstanding
- 5.27M
- Employees
- 4
- Next earnings
- —
About Acurx Pharmaceuticals, Inc.
Acurx Pharmaceuticals, Inc. functions as a clinical-stage biopharmaceutical firm focused on developing innovative antibiotic treatments for bacterial infections. The company's primary drug candidate is ibezapolstat, an antibiotic that utilizes a novel mechanism of action by targeting the polymerase IIIC enzyme. Ibezapolstat has successfully completed Phase II clinical trials for addressing Clostridium difficile infections. Additionally, Acurx is progressing with ACX-375C, an investigational therapeutic suitable for both oral and injectable administration. This compound is being developed to combat various gram-positive bacteria, including resistant strains such as methicillin-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus, and penicillin-resistant Streptococcus pneumoniae. Acurx Pharmaceuticals, Inc. was established in 2017 and is headquartered in Staten Island, New York.
- ISIN
- US00510M2035
- Founded
- 2017
- Listed since
- Jun 25, 2021
- Exchange
- Nasdaq Capital Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Coegin Pharma ABNGM: COEGIN | $6.26M | Skr2.17 | -10.33% |
| COSCIENS Biopharma Inc.TSX: CSCI | $6.11M | CA$8.62 | +0.23% |
| Evogene Ltd.TASE: EVGN | $6.08M | ₪1.19 | -2.69% |
| Bio Green Med Solution, Inc.NasdaqCM: BGMS | $6.02M | $0.91 | +7.10% |
| Niki BioSolutions, Inc.NasdaqCM: NIKI | $5.97M | $2.03 | -49.25% |
| Can-Fite BioPharma Ltd.TASE: CANF | $5.94M | ₪3.04 | -3.00% |
| Cizzle Biotechnology Holdings PlcLSE: CIZ | $5.81M | £0.01 | -29.31% |
| OLIPASS CorporationKOSDAQ: A244460 | $5.72M | ₩— | — |
Figures last refreshed Oct 18, 2026.